• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 23, 2017

View Archived Issues

In the clinic

Spero Therapeutics Inc., of Cambridge, Mass., started a phase I safety, tolerability, and pharmacokinetics study of SPR-994, an orally administered carbapenem antibiotic, in healthy subjects. Read More

Financings

Helix BioPharma Corp., of Richmond Hill, Ontario, said it closed a private placement financing for gross proceeds of approximately C$3.9 million. Read More

Bench Press: BioWorld looks at translational medicine

Calcium flux into neurons is a key event in memory formation as well as neuronal signaling more generally, and calcium levels in neurons are tightly regulated by calcium binding proteins. Read More

ADC Therapeutics raises $200M to build momentum in antibody-drug conjugates

DUBLIN – ADC Therapeutics SA (ADCT) closed $200 million in a private financing round, the fourth largest on record for a European biopharmaceutical firm. Read More

News from the Liver Meeting

Cirius Therapeutics Inc., of San Diego, reported preclinical data showing stellate cell activation and expression of markers of fibrosis were reduced when mitochondrial pyruvate carrier was deleted from liver cells or when mitochondrial pyruvate carrier was attenuated with Cirius’ drug MSDC-0602K, which modulates the entry of pyruvate into the mitochondria. Read More

Other news to note

Titan Pharmaceuticals Inc., of South San Francisco, reported non-clinical data showing that its Proneura subdermal implant continuously released liothyronine dose dependently for more than six months at the 87th annual conference of the American Thyroid Association in Victoria, British Columbia. Read More

BRCA1 function compromised in Alzheimer’s disease

The BRCA genes were first discovered for their roles in gynecological cancers, with the most deleterious mutations in BRCA1 and BRCA2 raising a woman’s lifetime risk of breast or ovarian cancer from 7 percent to somewhere between 45 and 65 percent. Read More

Foresee inks first deal for phase III prostate cancer candidate

HONG KONG – Foresee Pharmaceuticals Co. Ltd. and TRPharm Ilac Sanayi Tic. A/S have entered an exclusive licensing and distribution agreement for the commercialization of Foresee’s most advanced asset, FP-001, a luteinizing hormone-releasing hormone-agonist therapy for prostate cancer, in Turkey and certain Middle East countries. Read More

Mongersen miss dings Celgene shares as analysts revisit Nogra deal

Analysts voiced no little skepticism in 2014 when Celgene Corp. acquired privately held Nogra Pharma Ltd. to get its hands on GED-0301 (mongersen), a phase III-ready, oral antisense DNA oligonucleotide targeting the Smad7 protein to treat moderate to severe Crohn’s disease (CD) and related indications. Read More

Astellas commits up to $124M to license Universal cell therapy tech

Astellas Pharma Inc.’s U.S.-based regenerative medicine center has agreed to pay Seattle-based Universal Cells Inc. up to $124 million for global rights to use its Universal Donor Cell technology in a new cell therapy for an undisclosed indication. Read More

Durect tumbles on Posimir miss as focus shifts to epigenetic regulator lead

Prospects for Durect Corp.’s Posimir (Saber-bupivacaine) dimmed dramatically with the late Thursday disclosure of a failed phase III study of the extended-release analgesic. Data from the PERSIST study, which had been designed to address a 2014 FDA complete response letter (CRL), showed a favorable trend but fell short of statistical significance on the primary endpoint of reducing pain on movement over the first 48 hours after surgery. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe